Welcome to LookChem.com Sign In|Join Free
  • or
7-Quinazolinecarboxylic acid, 1,2,3,4-tetrahydro-2,4-dioxo-, Methyl ester is a chemical compound belonging to the quinazolinecarboxylic acid family, characterized by its unique structure and potential medicinal properties. With the Chemical Abstracts Service (CAS) number 174252-31-7, 7-Quinazolinecarboxylic acid, 1,2,3,4-tetrahydro-2,4-dioxo-, Methyl ester is recognized for its stability and versatility in pharmaceutical research and drug development.

174074-88-5

Post Buying Request

174074-88-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

174074-88-5 Usage

Uses

Used in Pharmaceutical Research and Drug Development:
7-Quinazolinecarboxylic acid, 1,2,3,4-tetrahydro-2,4-dioxo-, Methyl ester is utilized as a key component in the development of new pharmaceuticals due to its potential medicinal properties. Its unique structure and stability make it a valuable candidate for further research and exploration in the medical field.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 7-Quinazolinecarboxylic acid, 1,2,3,4-tetrahydro-2,4-dioxo-, Methyl ester serves as a building block for the synthesis of various bioactive molecules. Its chemical properties allow for the creation of novel compounds with potential therapeutic applications.
Used in Drug Design and Optimization:
7-Quinazolinecarboxylic acid, 1,2,3,4-tetrahydro-2,4-dioxo-, Methyl ester is employed in drug design and optimization processes to improve the efficacy and safety of existing medications. Its unique structure can be modified to enhance the pharmacokinetic and pharmacodynamic properties of drug candidates.
Used in Biochemical Studies:
7-Quinazolinecarboxylic acid, 1,2,3,4-tetrahydro-2,4-dioxo-, Methyl ester is also used in biochemical studies to investigate its interactions with various biological targets, such as enzymes, receptors, and other proteins. Understanding these interactions can provide insights into the compound's potential therapeutic effects and mechanisms of action.
Used in Drug Synthesis:
7-Quinazolinecarboxylic acid, 1,2,3,4-tetrahydro-2,4-dioxo-, Methyl ester is utilized in the synthesis of various drug molecules, particularly those with quinazoline-based structures. Its versatility and stability make it an ideal starting material for the development of new pharmaceutical agents.

Check Digit Verification of cas no

The CAS Registry Mumber 174074-88-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,4,0,7 and 4 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 174074-88:
(8*1)+(7*7)+(6*4)+(5*0)+(4*7)+(3*4)+(2*8)+(1*8)=145
145 % 10 = 5
So 174074-88-5 is a valid CAS Registry Number.

174074-88-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl 2,4-dioxo-1H-quinazoline-7-carboxylate

1.2 Other means of identification

Product number -
Other names 2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid methyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:174074-88-5 SDS

174074-88-5Relevant academic research and scientific papers

SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES

-

Page/Page column 112-113, (2012/05/19)

The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS

-

Page/Page column 20; 48; 53-54, (2008/06/13)

The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, Z1, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 174074-88-5